1.Sales and profit
See section β- Equillium, Inc. lost $22.4M in fiscal 2025.
EQ Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Last close Β· Oct 23, 2026
$1.23
3.1%Hi! I read Equillium, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
β$22.4M
No. It lost money last year.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Equillium, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 18 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 13, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 25, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 13, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 3, 2025 | Q2 '25 | Time not announced | 8-K β |
| Apr 24, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 27, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 13, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Equillium, Inc. lost $22.4M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$22.8M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Equillium, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $80.7M | $71.0M | $40.9M | $22.6M | $30.3M |
| Debt incl. finance leases | $10.2M | $9.1M | β | β | β |
| Debt / equity | 0.2x | 0.3x | β | β | β |
| Interest coverage | β35.2x | β59.0x | β29.6x | β | β |
| Current ratio | 9.4x | 2.4x | 1.8x | 3.9x | 10.6x |
| Quick ratio | 9.4x | 2.4x | 1.8x | 3.9x | 10.6x |
| Total assets | $85.4M | $78.4M | $50.5M | $25.6M | $31.9M |
| Total liabilities | $18.9M | $46.5M | $28.0M | $6.5M | $3.3M |
| Shareholders' equity | $66.5M | $31.9M | $22.6M | $19.1M | $28.6M |
| Net debt (β = net cash) | β$70.5M | β$62.0M | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | 3 / 7 | 1 / 7 | 2 / 7 | 2 / 7 | 2 / 7 | β / 6 |
| Accruals ratio | β8.5% | β4.3% | β7.4% | β8.2% | β65.6% | 13.1% | 28.8% | 1.2% |
| Altman Z'' | 35.34 | 3.65 | 5.66 | 2.24 | β8.03 | β10.24 | β19.02 | β12.18 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | β | β | β | β | $15.8M | $36.1M | $41.1M | β |
| Research and development | $4.9M | $17.6M | $19.4M | $26.4M | $37.5M | $37.0M | $37.4M | $12.8M |
| Operating income | β$8.6M | β$26.7M | β$29.5M | β$37.8M | β$62.1M | β$14.5M | β$8.3M | β$23.6M |
| Interest expense | $2.6M | $0.3M | $1.1M | $1.1M | $1.1M | $0.5M | β | β |
| Pretax income | β$13.3M | β$25.6M | β$29.8M | β$39.1M | β$62.4M | β$12.8M | β$7.7M | β$22.4M |
| Income tax | β | β | $0.0M | $0.0M | $0.0M | $0.6M | $0.4M | $0.0M |
| Net income | β$13.3M | β$25.6M | β$29.8M | β$39.1M | β$62.4M | β$13.3M | β$8.1M | β$22.4M |
| Diluted EPS | β$1.09 | β$1.47 | β$1.46 | β$1.36 | β$1.85 | β$0.38 | β$0.23 | β$0.39 |
| Diluted shares | 0.01B | 0.02B | 0.02B | 0.03B | 0.03B | 0.03B | 0.04B | 0.06B |
| Cash flow | ||||||||
| Cash from operations | β$7.5M | β$22.9M | β$24.6M | β$32.1M | β$8.7M | β$21.8M | β$19.0M | β$22.7M |
| Capital expenditure | $0.0M | $0.1M | $0.2M | $0.1M | $0.3M | $0.1M | $0.1M | $0.0M |
| Free cash flow | β$7.6M | β$23.0M | β$24.8M | β$32.1M | β$9.0M | β$21.8M | β$19.1M | β$22.8M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $0.4M | $2.3M | $3.8M | $4.4M | $4.8M | $4.0M | $3.8M | $2.3M |
| Share buybacks | β | β | β | β | β | $0.3M | β | β |
| Dividends and buybacks | β | β | β | β | β | $0.3M | β | β |
| Balance sheet | ||||||||
| Cash and short-term investments | $65.9M | $53.1M | $82.2M | $80.7M | $71.0M | $40.9M | $22.6M | $30.3M |
| Total debt | β | $9.7M | $9.9M | $10.2M | $9.1M | β | β | β |
| Current assets | $67.1M | $55.4M | $85.2M | $83.4M | $76.7M | $49.3M | $25.0M | $31.0M |
| Current liabilities | $2.0M | $3.9M | $7.2M | $8.9M | $32.0M | $27.6M | $6.4M | $2.9M |
| Property and equipment, net | $0.1M | $0.1M | $0.2M | $0.2M | $0.4M | $0.3M | $0.3M | $0.2M |
| Total assets | $67.2M | $55.5M | $85.4M | $85.4M | $78.4M | $50.5M | $25.6M | $31.9M |
| Total liabilities | $2.2M | $13.7M | $15.6M | $18.9M | $46.5M | $28.0M | $6.5M | $3.3M |
| Shareholders' equity | $64.9M | $41.8M | $69.9M | $66.5M | $31.9M | $22.6M | $19.1M | $28.6M |
| Margins | ||||||||
| Operating margin | β | β | β | β | β393.9% | β40.2% | β20.1% | β |
| EBITDA margin | β | β | β | β | β393.2% | β39.9% | β19.8% | β |
| Net margin | β | β | β | β | β396.1% | β37.0% | β19.6% | β |
| FCF margin | β | β | β | β | β57.2% | β60.5% | β46.5% | β |
| Returns | ||||||||
| Return on capital employed | β13.2% | β51.7% | β37.8% | β49.4% | β133.8% | β63.3% | β43.0% | β81.6% |
| Return on equity | β20.4% | β47.9% | β53.4% | β57.3% | β126.8% | β48.9% | β38.8% | β94.0% |
| Return on assets | β19.7% | β41.7% | β42.3% | β45.7% | β76.2% | β20.7% | β21.2% | β77.9% |
| Return on tangible equity | β20.4% | β61.2% | β42.7% | β58.7% | β195.4% | β59.1% | β42.3% | β78.3% |
| Growth | ||||||||
| Revenue growth | β | β | β | β | β | 129.0% | 13.9% | β |
| Share count change | β | 42.6% | 17.1% | 41.5% | 17.1% | 3.0% | 1.8% | 62.1% |
| Financial health | ||||||||
| Debt / equity | β | 0.2x | 0.1x | 0.2x | 0.3x | β | β | β |
| Interest coverage | β3.4x | β95.8x | β26.9x | β35.2x | β59.0x | β29.6x | β | β |
| Current ratio | 33.1x | 14.3x | 11.8x | 9.4x | 2.4x | 1.8x | 3.9x | 10.6x |
| Quick ratio | 33.1x | 14.3x | 11.8x | 9.4x | 2.4x | 1.8x | 3.9x | 10.6x |
| Capital allocation | ||||||||
| Capex / revenue | β | β | β | β | 1.8% | 0.1% | 0.2% | β |
| Stock comp / revenue | β | β | β | β | 30.7% | 11.1% | 9.1% | β |
| Quality scores | ||||||||
| Piotroski F-score | β | β | 3.0 | 1.0 | 2.0 | 2.0 | 2.0 | β |
| Altman Z'' | 35.3 | 3.7 | 5.7 | 2.2 | β8.0 | β10.2 | β19.0 | β12.2 |
| Accruals ratio | β8.5% | β4.3% | β7.4% | β8.2% | β65.6% | 13.1% | 28.8% | 1.2% |
Source: SEC EDGAR XBRL filings (CIK 0001746466). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.